Antithrombotic Therapy Improves ICU Mortality of Septic Patients with Peripheral Vascular Disease in Shebin Elkom Teaching Hospital

Background One of the main reasons critically ill patients suffer from severe illness and pass away, especially those who already have peripheral vascular disease (PVD), is sepsis. Sepsis's hypercoagulable condition exacerbates microvascular thrombosis, resulting in organ damage and unfavorable clinical outcomes. Antithrombotic treatment options, such as anticoagulants, antiplatelet medications, or a combination of these, have the potential to improve sepsis patients' prognosis. Objective In this study, septic patients with peripheral vascular disease (PVD) who were admitted to Shebin Elkom Teaching Hospital are examined for the effects of antithrombotic therapy on ICU mortality and clinical outcomes. Methods 112 septic ICU patients with PVD were prospectively followed and classified according to the type of antithrombotic treatment they received: dual therapy, anticoagulant, antiplatelet, or none at all. SOFA scores, INR, and heart failure status were among the clinical and laboratory metrics that were recorded. The study employed Kaplan-Meier curves to assess survival and Cox regression to find predictors of ICU mortality. Results Compared to no therapy, the use of antithrombotic therapy was linked to a significant decrease in intensive care unit mortality (33.3% vs. 64.7%, p = 0.002). The treatment group with the lowest mortality rate, dual therapy, had a 20.0% rate. According to Kaplan-Meier survival analysis, antithrombotic treatment significantly improved survival (log-rank p = 0.004). The absence of antithrombotic therapy (HR: 5.9, p = 0.007) and heart failure (HR: 2.7, p = 0.018) turned out to be independent variables. that predicted ICU mortality using Cox regression analysis. Conclusion In septic patients with PVD, antithrombotic therapy has been demonstrated to increase survival and lower ICU mortality, particularly when used in conjunction with dual therapy. These findings highlight how crucial customized antithrombotic treatment regimens are for critically ill patients with vascular comorbidities and sepsis.